Tags

Type your tag names separated by a space and hit enter

Reversible monoamine oxidase-A inhibitors in resistant major depression.
Clin Neuropharmacol. 1993; 16 Suppl 2:S69-76.CN

Abstract

Monoamine oxidase (MAO) inhibitors (MAOIs) provide effective alternative therapy for those patients with major depression who do not respond to tricyclic antidepressants or such related compounds as the selective serotonin reuptake inhibitors. This article reviews studies on the efficacy of both the classical MAOIs and the new, selective monoamine oxidase-A (MAO-A) inhibitor brofaromine in patients with resistant major depression. Brofaromine appears to be as effective as the older MAOIs in these patients, but is better tolerated and safer to use. Brofaromine was also found to be better tolerated than lithium when added to treatment with the tetracyclic antidepressant maprotiline. More studies on the benefits of the new MAO-A inhibitors in resistant depression are indicated, not only with brofaromine but also with moclobemide, which to date has not been studied in this indication. Studies to determine their place in the overall treatment strategy of major depression are also needed.

Authors+Show Affiliations

Department of Biological Psychiatry, Psychiatric Centre Bloemendaal, The Hague, The Netherlands.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

8313400

Citation

Nolen, W A., et al. "Reversible Monoamine oxidase-A Inhibitors in Resistant Major Depression." Clinical Neuropharmacology, vol. 16 Suppl 2, 1993, pp. S69-76.
Nolen WA, Hoencamp E, Bouvy PF, et al. Reversible monoamine oxidase-A inhibitors in resistant major depression. Clin Neuropharmacol. 1993;16 Suppl 2:S69-76.
Nolen, W. A., Hoencamp, E., Bouvy, P. F., & Haffmans, P. M. (1993). Reversible monoamine oxidase-A inhibitors in resistant major depression. Clinical Neuropharmacology, 16 Suppl 2, S69-76.
Nolen WA, et al. Reversible Monoamine oxidase-A Inhibitors in Resistant Major Depression. Clin Neuropharmacol. 1993;16 Suppl 2:S69-76. PubMed PMID: 8313400.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Reversible monoamine oxidase-A inhibitors in resistant major depression. AU - Nolen,W A, AU - Hoencamp,E, AU - Bouvy,P F, AU - Haffmans,P M, PY - 1993/1/1/pubmed PY - 1993/1/1/medline PY - 1993/1/1/entrez SP - S69 EP - 76 JF - Clinical neuropharmacology JO - Clin Neuropharmacol VL - 16 Suppl 2 N2 - Monoamine oxidase (MAO) inhibitors (MAOIs) provide effective alternative therapy for those patients with major depression who do not respond to tricyclic antidepressants or such related compounds as the selective serotonin reuptake inhibitors. This article reviews studies on the efficacy of both the classical MAOIs and the new, selective monoamine oxidase-A (MAO-A) inhibitor brofaromine in patients with resistant major depression. Brofaromine appears to be as effective as the older MAOIs in these patients, but is better tolerated and safer to use. Brofaromine was also found to be better tolerated than lithium when added to treatment with the tetracyclic antidepressant maprotiline. More studies on the benefits of the new MAO-A inhibitors in resistant depression are indicated, not only with brofaromine but also with moclobemide, which to date has not been studied in this indication. Studies to determine their place in the overall treatment strategy of major depression are also needed. SN - 0362-5664 UR - https://www.unboundmedicine.com/medline/citation/8313400/Reversible_monoamine_oxidase_A_inhibitors_in_resistant_major_depression_ L2 - http://www.diseaseinfosearch.org/result/2199 DB - PRIME DP - Unbound Medicine ER -